ArcherDX
Boulder
About ArcherDX
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $150.0M
- Funding stage: M&A
- Last round: Series C (Dec 2019)
- Website: archerdx.com
- Phone: (877) 771 1093
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/archerdx-80546 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.